Trial Profile
Long Term, Open-Label, Safety Follow Up Study Following Transplantation Of Pf-05206388 (Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE)) In Subjects With Acute Wet Age Related Macular Degeneration And Recent Rapid Vision Decline
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 24 Nov 2023
Price :
$35
*
At a glance
- Drugs PF 5206388 (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors Pfizer
- 21 Nov 2023 Planned initiation date changed from 21 May 2023 to 21 Jan 2024.
- 14 Mar 2023 Planned End Date changed from 4 Oct 2020 to 30 May 2033.
- 14 Mar 2023 Planned primary completion date changed from 4 Oct 2020 to 30 May 2033.